Metabolic Disorders in Polycystic Ovarian Syndrome

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2004 by National Taiwan University Hospital.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
National Taiwan University Hospital
ClinicalTrials.gov Identifier:
NCT00172523
First received: September 12, 2005
Last updated: NA
Last verified: October 2004
History: No changes posted

September 12, 2005
September 12, 2005
October 2004
Not Provided
Not Provided
Not Provided
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Metabolic Disorders in Polycystic Ovarian Syndrome
Not Provided

The purpose of this study is to elucidate the significance of adipocytokine in women with PCOS among adiposity, hyperandrogenism and insulin resistance.

Polycystic ovary syndrome (PCOS) is the most common endocrinopathy in women of reproductive age with a probable prevalence of 5% to 10%. PCOS is characterized by chronic anovulation, menstrual irregularities, evidence of hyperandrogenism (either clinical, manifested as hirsutism, acne, male pattern balding, or biochemical, manifested by elevated serum adrenal and/or ovarian androgen concentration). Fifty percent of all patients with PCOS are obese, and the presence of obesity affects the clinical manifestations of PCOS. The underlying pathogenic mechanisms appear to involve insulin resistance and hyperinsulinemia, the magnitude of which is greater in obese than in non-obese women with PCOS.

Observational
Observational Model: Defined Population
Time Perspective: Cross-Sectional
Not Provided
Not Provided
Not Provided
Not Provided
Polycystic Ovary Syndrome
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
Not Provided
August 2005
Not Provided

Inclusion Criteria:

  • 1. Oligomenorrhea ( less than 6 times spontaneous MC per year) or Amenorrhea. 2. Hyperandrogenism (either clinical or biochemistry. 3. PCO by ultrasound. 4.After menarche, before menopause.

Exclusion Criteria:

  • 1. hormone therapy in the past 6 months. 2. Pregnancy in the past 6 months 3.Acute illness found in the past 3 months. 4.Systemic disease including autoimmune disease, malignancy, hepatic, renal or CVS disease, and ever received chemotherapy or immunosuppressive agents.
Female
17 Years to 40 Years
No
Contact: Mei-Jou Chen, M.D. 886-2-23123456 ext 3950 metro@ha.mc.ntu.edu.tw
Taiwan
 
NCT00172523
9361701094
Not Provided
Not Provided
National Taiwan University Hospital
Not Provided
Study Director: Horng-Nerng Ho, M.D. NTUH
National Taiwan University Hospital
October 2004

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP